|
Tobacco Product Disease Risks
|
Research Initiative
|
FDA
|
NCI
|
NCI and the FDA-Center for Tobacco Products, in collaboration with the US Census Bureau, co-lead this study, which harmonizes data on cigarette, cigar, and pipe use from various Tobacco Use Supplements that have been administered over the years as part of the Current Population Survey. The participants in these surveys have been followed for mortality by linkage to the National Death Index. These data are used to provide contemporary estimates of the mortality risks of daily and non-daily use of cigarettes, pipes, and cigars.
|
|
Tobacco Regulatory Science Program (TRSP)
|
Research Initiative
|
FDA
|
OD/DPCPSI/ODP, CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIEHS, OD/OER
|
Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources.
|
|
Tobacco Use Supplement to Current Population Survey (TUS-CPS)
|
Health Survey
|
CDC, FDA
|
NCI, NIMHD
|
The Tobacco Use Supplement to the Current Population Survey (TUS-CPS) is an NCI-sponsored survey of tobacco use that has been administered as part of the US Census Bureau'sCurrent Population Survey approximately every 3-4 years since 1992-93.
|
|
Toxicology in the 21st Century (Tox 21)
|
Resource Development
|
FDA
|
NCATS, NIEHS
|
The Toxicology in the 21st Century (Tox21) program is a federal collaboration among National Institutes of Health(NIH) National Center for Advancing Translational Science (NCATS) and the National Toxicology Program at the National Institute of Environmental Health Sciences; the Environmental Protection Agency; and the Food and Drug Administration. Tox21 researchers aim to develop better toxicity assessment methods to quickly and efficiently test whether certain chemical compounds have the potential to disrupt processes in the human body that may lead to negative health effects.
|
|
Toxicology in the 21st Century Federal Consortium: NCATS Interagency Agreement, ES-7020-01, Year 11 (Tox21)
|
Research Initiative
|
FDA
|
NIEHS, NCATS
|
Tox21 is a US federal research collaboration focused on driving the evolution of Toxicology in the 21st Century by developing methods to rapidly and efficiently evaluate the safety of commercial chemicals, pesticides, food additives/contaminants, and medical products.
This IAA is designed to explore new, effective, primarily non-animal methods and technologies to elucidate critically important questions pertaining to impacts of environmental exposures on cellular toxicity pathways that may lead to human disease. A major focus is the development of innovative approaches in toxicology assessment.
|
|
Toxicology in the 21st Century Program (Tox21) - Computational Toxicology
|
Research Initiative
|
FDA
|
NCATS
|
Toxicology in the 21st Century Program (Tox21) - Computational Toxicology
|
|
Toxicology in the 21st Century Program (Tox21) - Systems Toxicology
|
Research Initiative
|
FDA
|
NCATS
|
Toxicology in the 21st Century Program (Tox21) - Systems Toxicology
|
|
Toxin Working Group of the Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
The workgroup holds biweekly meetings to discuss the following: point of regulation of select toxins (Botulinum neurotoxins, Staphylococcal enterotoxins, Abrin, Ricin, Conotoxins, Saxitoxin, Tetrodotoxin, Diacetoxyscirpenol, T-2 toxin), natural environment, toxin exclusion limits, space decontamination, and potential updates to the Centers for Disease Control and Prevention (CDC) manual “Biosafety in Microbiological and Biomedical Laboratories.”
|
|
Toxins Assessment Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ASPR, CDC, FDA
|
NIAID
|
Biological (not engineered) toxins with specific effects on the nervous system, focusing on neurotoxins, applications in medical research and historical consideration as bioweapons
|
|
Tracking Resistance and Coronavirus Evolution (TRACE)
|
Research Initiative
|
ASPR, CDC, FDA
|
NCATS, NIAID
|
The ACTIV Tracking Resistance and Coronavirus Evolution (TRACE) initiative is focused on identifying emerging variants of SARS-CoV-2, the coronavirus that causes COVID-19 disease. The initiative is surveying new viral variants, assessing vaccine and therapeutic resistance, and evaluating the impact of genetic variation on viral biology and on the clinical approaches for preventing and treating illness. TRACE aims to prioritize which viral variants should be studied to determine the effectiveness of vaccines and therapeutics currently in late stages of development against these variants; coordinate data sharing; and confirm testing and periodic (e.g. weekly) public reporting of results to allow confident decision making by the U.S. Government (USG), health professionals, and pharmaceutical organizations. The initiative, which is being led by NIH and facilitated by the Foundation for the National Institutes of Health, with participation by the ACTIV public-private partners, is developing the infrastructure and processes for monitoring and testing emerging SARS-CoV-2 variants and standardizing, gathering, and sharing variant sequencing data.
|